Selecta Biosciences (SELB Stock): returns 14.5% on a red week
|Selecta Biosciences, Inc., is a clinical-stage biopharmaceutical company, which researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Market Cap: US$347.1M
One Year Return 107.7%
Over the past 2 weeks, we've seen significant insider buying at SELB (2) which can be construed as a positive sign for higher share prices. Since the 2018 decline, SELB's share price has ranged much throughout 2019 to present and is now testing the multi-year inside trendline at (1). It has to be said that this week the share price has held up quite well considering the sharp sell-off on the U.S. Indexes. Confirmation that SELB is finally about to break out of its long term bottoming pattern, will become apparent if we can convincingly break, hold and close above the inside trendline on the weekly time frame, preferably above the 4.70 handle, which in turn should invite more investors to the table.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.